About a quarter of the 200 colonized patients had clinical illness, including 27 with bloodstream infections.
If illness from the fungus becomes more common, "We are dealing with the potential for a highly resistant bug to really take off."
A new fluoroquinolone antibiotic, delafloxacin (Baxdela), for acute bacterial skin and skin structure infections (ABSSSI) in adults gained approval yesterday from the US Food and Drug Administration (FDA), according to Melinta Therapeutics, the manufacturer.
In today's Morbidity and Mortality Weekly Report, investigators from the Centers for Disease Control and Prevention (CDC) and several state health departments say a total of 77 clinical cases of the emerging multidrug-resistant fungus Candida auris have now been reported from seven states.
The Pew Charitable Trusts has released a set of recommendations for how to ensure more appropriate use of antibiotics in animal agriculture.